Homocysteine in patients with diabetes mellitus;Homocisteína en el paciente con diabetes mellitus

Medicina Clinica

Volumn 122, Issue 1, 2004, Pages 27-32

  De Luis, Daniel ^a,b   Fernández, Nuria ^a   Aller, Rocío ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Inst de Endocrinologia y Nutricion   (Spain)

Author keywords

Chronic complications; Diabetes mellitus; Homocysteine

Indexed keywords

AMINO ACID; HOMOCYSTEINE; METHIONINE; PROTEIN; THIOL GROUP;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC RETINOPATHY; DIETARY INTAKE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIUM LESION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; METABOLISM; MICROVASCULATURE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; REVIEW; RISK FACTOR; THROMBOGENESIS; THROMBOSIS; VASCULAR DISEASE;

EID: 1142267487     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(04)74130-5     Document Type: Review

References (38)

1. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
2. Mato JM, Álvarez L, Ortiz P, Pajares MA. S-adenosylmethionine syntesis: molecular mechanism and clinical implications. Pharmacol Ther 1997;73:265-80.
3. Holven K, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, et al. Effect of folic acid treatment on endothelium-dependent vasodilatation and nitric oxiderived end products in Hyperhomocysteinemic subjects. Am J Med 2001;110:536-42.
4. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.
5. Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a posible mechanism for trombosis. Blood 2000; 96:966-72.
6. Welch A, Upchurch GR Jr, Farivar RS, Pigazzi A, Vu K, Brecher P, et al. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappaB-dependent transcriptional activation of Nos2. Proc Assoc Am Phys 1998;110:22-31.
7. Harpel PC, Chang VT, Burth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential link between trombosis, atherogenesis, and sulfhydryl group compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-7.
8. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
9. OK, Lynn EG, Chung YH, Siow YL, Man RY, Choy PC. Homocysteine stimulates the production and secretion of colesterol in hepatic cells. Biochim Biophys Acta 1998;1393:317-24.
10. Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in non diabetic but not type 2 diabetic subjects. Metabolism 1998; 47:686-9.
11. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis 1998; 139:197-8.
12. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, et al. Homocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998;18: 133-8.
13. Stenhouwer CDA, Fischer HRA, Van Kuijk AW, Polak BC, Donker AJ. Endotelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995;44:561-4.
14. Chico A, Pérez A, Córdoba Porras A, Arcelus R, Carreras G, de Leiva A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus. A new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998;41:684-93.
15. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkes M, et al. Hyperhomocist(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;20:1880-6.
16. Cronin C, McPartlin J, Barry DG, Ferriss JB, Scott JM, Weir DG. Plasma homocysteine concentration in patients with type 1 diabetes. Diabetes Care 1998;21:1843-7.
17. Robillon JF, Canivet B, Candito M, Sadoul JL, Jullien D, Morand P, et al. Type 1 diabetes mellitus and homocyst(e)ine. Diabetes Metab 1994;20: 494-9.
18. Foreman JW, Wald H, Blumberg G, Pepe LM, Segal S. Homocysteine uptake in isolated rat renal cortical tubules. Metabolism 1982;31:613-9.
19. Hultberg B, Agardh E, Andersson A, Brattstrom L, Isaksson A, Israelsson B, et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab 1991;51:277-82.
20. Vaccaro O, Ingrosso D, Rivellese A, Greco G, Riccardi G. Moderate hyperhomocysteinemia and retinopathy in insulin-dependent diabetes. Lancet 1997;349:1102-3.
21. Salardi S, Cacciari E, Sassi S, Grossi G, Mainetti B, Dalla Casa C, et al. Homocysteinemia, serum folate and vitamin B in very young patients with diabetes mellitus type 1. J Pediatr Endocrinol Metab 2000;13:1621-7.
22. Beks PJ, Machali AJC, De Neeling JND, De Vries H, Bouter LM, Heine RJ. Peripheral arterial disease inrelation to glycaemic level in an elderly Caucasian population: the Hoorn Study. Diabetologia 1995;38:86-96.
23. Hoogeveen EK, Kostense PJ, Eysink PE, Valk GD, Jakobs C, Dekker JM, et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn Study. Arch Intern Med 2000;160:2984-90.
24. Hoogeven EK, Kostense PJ, Eysink PE, Polak BC, Beks PJ, Jakobs C, et al. Hyperhomocysteinemia is not related to risk of distal somatic polyneuropathy: the Hoorn Study. J Intern Med 1999;246:561-6.
25. Buysschaert M, Wallemacq PE, Dramais A-S, Hermans MP. Hyperhomocysteinemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000;23:1816-22.
26. Stabler S, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW. Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism 1999;48:1096-101.
27. Ambrosch A, Dierkes J, Lobmann R, Kuhne W, Konig W, Luley C, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabet Med 2001;18:185-92.
28. Meigs JB, Jacques P, Selhub J, Cupples LA, Nathan Dm, Singer DE. Elevated plasma homocysteine levels are more prevalent amog Framingham Offspring Study subjects with the insulin resistance syndrome. Diabetes 1999;48(Suppl 1):A165.
29. Hrnciar J, Gabor D, Hrnciarova M, Okapcova J, Szentivanyi M, Kurray P. Relation between cytokines (TNF-alpha, IL-1 and 6) and homocysteine in android obesity and the phenomenon of insulin resystance syndromes. Vnitr Lek 1999;45:11-6.
30. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001;24:533-8.
31. Bar-On H, Kidron M, Friedlander Y, Ben-Yehuda A, Selhub J, Rosenberg IH, et al. Plasma total homocysteine levels in subjects with hyperinsulinemia. J Intern Med 2000;247:287-94.
32. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999;55:1028-35.
33. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odelkerken DA, et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125-32.
34. Bañoga BS, Reynolds T, Fink LM, Fonseca VA. Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocr Pract 2000;6:435-41.
35. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese with type 2 diabetes. Diabetes Care 1999;22:484-90.
36. Seghieri G, Breschi MC, Anichi R, De Bellis A, Alviggi L. Serum homocysteine levels are increased in women with gestational diabetes mellitus. Metabolism 2003;52:720-3.
37. Da de Luis, Arranz M, Domínguez N, Izaola O, Aller R. Total homocysteine and cognitive deteroration in patients with diabetes type 2. Diabetes Res Clin Pract 2002;55:185-90.
38. Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide Arberas MV, Ruiz Gutiérrez M, Aguirre Erraste C. Homocisteína plasmática en pacientes con lupus eritematoso sistémico. Med Clin (Barc) 2003;120:681-5.